Filing summary
Entity discrepancy: The supplied filing is for Access Pharmaceuticals, Inc., not Abeona Therapeutics Inc. It is a Form 10-Q for the quarter ended June 30, 2011; the financial statements are unaudited. Verify that this is the intended filing before relying on the figures below.
Business context and reporting period
Access described itself as an emerging biopharmaceutical company developing drug-delivery and nanopolymer technologies. Its portfolio included launched MuGard for oral mucositis; Phase 2 ProLindac; Phase 1/2 Thiarabine; and preclinical oral insulin, CobOral and CobaCyte programs. MuGard was launched in the United States in late 2010 and in several European markets through a partner.
Financial results and position
| Metric | Three months ended June 30, 2011 | Six months ended June 30, 2011 |
|---|---|---|
| Total revenue | $151,000 | $301,000 |
| Operating expenses | $2.404 million | $4.703 million |
| Loss from operations | $2.253 million | $4.402 million |
| Net income (loss) | $(1.264) million | $(3.163) million |
| Net income (loss) allocable to common stockholders | $(1.706) million | $(4.043) million |
| Loss per common share, basic and diluted | $(0.09) | $(0.21) |
| Net cash used in operating activities | Not provided for quarter alone | $2.648 million |
Revenue for the first half included $174,000 in license revenue, $30,000 in sponsored research revenue, $41,000 in royalties and $56,000 in MuGard product sales. MuGard product costs were $358,000 for the period, exceeding product sales; the filing does not present a consolidated gross-margin measure. Management reported an approximate net cash burn of $436,000 per month.
At June 30, cash and cash equivalents were $4.346 million, total current assets were $4.472 million, and the working-capital deficit was $8.4 million. Total liabilities were $29.004 million; stockholders’ deficit was $23.939 million. The balance sheet included $5.5 million of convertible-note principal, divided between $2.75 million current and $2.75 million long-term. Accumulated deficit was $255.178 million.
Changes versus the prior comparable period
- First-half revenue rose to $301,000 from $207,000, including new sponsored research and U.S. MuGard sales; licensing revenue was unchanged at $174,000.
- First-half operating expenses increased to $4.703 million from $3.790 million, primarily as research and development spending rose to $2.180 million from $1.519 million. General and administrative expense declined to $2.045 million from $2.151 million.
- Common-stockholder results changed from $1.991 million of first-half income in 2010 to a $4.043 million loss in 2011. The comparison was affected by lower noncash gains on warrant derivatives in 2011 ($2.174 million versus $6.238 million) and the absence of the prior-year $509,000 gain from negotiated payables and write-offs; 2011 also recorded a $420,000 loss on the preferred-stock derivative.
- Cash declined by $2.687 million during the first half, from $7.033 million to $4.346 million. The company reported no financing cash inflows in the period, compared with $5.988 million in the first half of 2010.
Outlook, risks and other significant matters
- Management said existing resources and expected license receipts were expected to fund the current operating level into the first quarter of 2012, but additional financing was needed within 12 months. It warned that failure to obtain capital or licensing arrangements could jeopardize operations and its ability to continue as a going concern.
- The $5.5 million convertible note was originally due September 13, 2011. Under an agreement announced July 12 and amended August 15, 2011, $2.75 million was extended to September 13, 2012; the other $2.75 million was payable by the earlier of December 1, 2011 or an equity financing. If that payment was not made by December 1, the full $5.5 million plus accrued interest would become due December 13, 2011. The amended terms gave the noteholder security interests in certain assets.
- Series A preferred dividends accrued totaled $5.446 million at June 30. The company also reported $857,000 of accrued liquidated damages related to registration-statement obligations. Preferred shares carried a 6% annual dividend, payable semi-annually in cash or, in certain circumstances, common stock.
- Management disclosed that disclosure controls were not effective and an unremediated material weakness remained, related to oversight of the CFO’s financial-reporting work, limited accounting staff, lack of segregation of duties and technical accounting expertise. Management said this weakness had not caused a restatement and did not believe it affected the current-period financial statements.
- Key business uncertainties included clinical and regulatory outcomes, commercialization and reimbursement of MuGard, dependence on partners, and access to financing. Management reported no legal proceedings believed to have a material financial impact. It provided no quantitative financial guidance beyond the stated cash runway.
Important facts for investors to verify
- Confirm the intended issuer: the filing identifies Access Pharmaceuticals, Inc., not Abeona Therapeutics Inc.
- Review the amended note agreement, payment deadlines, collateral terms and whether the required payments or financing were completed.
- Assess the company’s cash runway against its operating burn, working-capital deficit and stated need for additional funding.
- Verify the status of preferred dividends, registration-related liquidated damages, and potential dilution from preferred-stock conversion and other securities.
- Track MuGard sales, reimbursement access and partner-led market approvals, alongside clinical progress and funding for development programs.
- Consider the continuing material weakness in internal control and the significant effect of derivative fair-value changes on reported earnings.